Medical complications of SSRI and SNRI treatment

Primary Psychiatry

Volumn 15, Issue 2, 2008, Pages 37-41

  Sussman, Norman ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CITALOPRAM; FENTANYL; FLUOXETINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; OPIATE; PENTAZOCINE; PETHIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAMADOL; TRIPTAN DERIVATIVE;

ADULT; AGED; ANHEDONIA; BLEEDING; BODY WEIGHT; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EMOTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPONATREMIA; LABORATORY TEST; LIBIDO; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PANIC; PHYSICAL EXAMINATION; PRESCRIPTION; QUALITY OF LIFE; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SLEEP; UNNECESSARY PROCEDURE; WEIGHT GAIN;

EID: 39749097747     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Looper KJ. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics. 2007;48(1):1-9.
2. Phillips B. Rule of three. Arch Dis Child. 2005;90(6):642.
3. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture. 1994. J R Coll Physicians Lond. 1995;29:41-49.
4. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006:119(2):113-116.
5. Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother. 1992;26(12):1517-1519.
6. Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopaedic surgical patients. Arch Intern Med. 2003;163(19):2354- 2358.
7. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106-1109.
8. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164(21): 2367-2370.
9. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2007;27(1):31-40.
10. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38(11):3049-3051.
11. Weinrieb RM, Auriacombe M, Lynch KG, Lewis JD. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf. 2005;4(2):337-344.
12. Goh KP. Management of hyponatremia. Am Fam Physician. 2004;69(10):2387-2894.
13. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40(9):1618-1622).
14. Amsterdam JD, Garcia-España F, Goodman D, Hooper M, Hornig-Rohan M. Breast enlargement during chronic antidepressant therapy. J Affect Disord. 1997;46(2):151-156.
15. Marcus P. SSRIs and mammoplasia. Am J Psychiatry. 2001;158(6):967.
16. Ashton AK, Longdon MC. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants. Am J Psychiatry. 2007;164(7):1121-1122.
17. Sahin M, Yilmaz H, Guvener ND. A possible case of gynecomastia with fluoxetine. Ann Pharmacother. 2005;39(7-8):1369.
18. Teitelbaum M. Severe hypertriglyceridemia secondary to venlafaxine and fluoxetine. Psychosomatics. 2001;42(5):440-441.
19. Lara N, Baker GB, Archer SL, Le Mellédo JM. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry. 2003;64(12):1455-1459.
20. Bailey PD, Le Melledo JM. Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorder. J Clin Psychopharmacol. 2003;23(3):317-319.
21. Battaglino R, Vokes M, Schulze-Späte U, et al. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem. 2007;100(6):1387-1394.
22. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(12):1240-1245.
23. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167(12):1246-1251.
24. Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs. Anesth Analg. 2006;103(6):1466-1468.
25. FDA public health advisory: combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. U.S. Food and Drug Administration. Available at: www.fda.gov/cder/drug/advisory/SSRI_SS200607.htm. Accessed January 10, 2008.
26. Evans RW. The fda alert on serotonin syndrome with combined use of ssris or snris and triptans: an analysis of the 29 case reports. Medscape General Medicine. Available at: http://medgenmed.medscape.com/viewarticle/561741. Accessed January 10, 2008.
27. Yirmiya R, Goshen I, Bajayo A, et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A. 2006;103(45):16876-16881.
28. Tanrikut C, Schlegel PN. Antidepressant-associated changes in semen parameters. Urology. 2007;69(1)185.